[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [RiskSubgroup](https://github.com/mm80843/T3.5/tree/pages/docs/RiskSubgroup/index.md) >> Individual ID:PBN__RiskSubgroup_37 

# __Lack of effective medical solutions__

## Risks in this RiskSubgroup

* [Absence of approved therapy for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3369.md)
* [Absence of covid-19 treatment and delayed availability of vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2250.md)
* [Absence of efficacy studies in clinical settings](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1172.md)
* [Absence of specific treatment or vaccine for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_854.md)
* [Accumulating evidence on the efficacy and duration of natural immunity contributing to the mitigation of the covid-19 pandemic](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2324.md)
* [Adverse health effects of uvgi on humans](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1733.md)
* [Aerosolization and sampling can lead to survival of infectious viruses, increasing the risk of disease transmission](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1341.md)
* [Aggregate average public demand for local-level vector control by authorities is dictated by the infected human population.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2159.md)
* [Air conditioning contributing to the spread of the virus in indoor environments](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_966.md)
* [Airborne spread of covid-19 in healthcare facilities](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1957.md)
* [Airborne transmission of covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_849.md)
* [Antibiotic overuse leading to drug resistance and ineffective treatment of infectious diseases.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1220.md)
* [Assuming 80% efficacy of personal protective measures against mosquitos may lead to underestimation of transmission rates and disease spread.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1483.md)
* [Asymptomatic and flu-like symptoms of sars-cov-2](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2277.md)
* [Breakthrough infections despite vaccine launch](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1528.md)
* [Challenges in face-to-face consultations during the covid-19 pandemic](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2684.md)
* [Chronic under-funding of the world health organization who leading to limited resources for global health governance.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_423.md)
* [Complex temporal role of urban density in the spread of the virus](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2085.md)
* [Concentration loss and stress as part of sick building syndrome](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2165.md)
* [Considerable uncertainty in transmission reduction estimates for npis](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1139.md)
* [Contagious diseases propagation due to sick building syndrome symptoms like red/watery eyes, runny/blocked nose, itchy/dry throat and skin.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1589.md)
* [Contagious diseases propagation within interconnected supply chains.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3380.md)
* [Contagious transmission of pathogens in public settings](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1891.md)
* [Contamination of frequently touched surfaces](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_133.md)
* [Contamination of indoor air with volatile organic compounds vocs](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_702.md)
* [Contamination of object surfaces](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_967.md)
* [Contamination of surfaces](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_692.md)
* [Contamination of surfaces with pathogens](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2643.md)
* [Conversion of non-medical spaces into medical facilities during outbreaks](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1324.md)
* [Covid-19 pandemic highlighting the importance of hvac design and operations](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_921.md)
* [Covid-19 transmission](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1413.md)
* [Cytokine bursts caused by vaccine leading to acute respiratory distress syndrome ards](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1539.md)
* [Cytotoxicity of graphene derivatives due to negatively charged groups](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_54.md)
* [Delay in developing an effective vaccine for covid-19.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_935.md)
* [Delay in the development of a commercially viable vaccine for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2675.md)
* [Demand for vaccine development](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_657.md)
* [Dependence of virus stability on temperature](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_519.md)
* [Dependence on concentration and exposure time](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_861.md)
* [Dependency on the development of a vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_41.md)
* [Differences in survival rates of viruses in different suspension media can impact disease transmission](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2909.md)
* [Difficulty in inactivating sars-cov-1 and mers-cov compared to influenza a](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_225.md)
* [Difficulty in vaccine distribution](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1169.md)
* [Disease severity in re-infected patients](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1500.md)
* [Disinfectant fogging systems may pose a health risk if not properly regulated and applied, leading to exposure of building occupants to harmful chemicals.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2996.md)
* [Effect of humidity on virus viability](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1300.md)
* [Effect of nebulization and liquid impingement on the survival of animal viruses](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1890.md)
* [Effectiveness and limitations of disinfectants in eliminating microorganisms on various surfaces.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_862.md)
* [Effectiveness of biocidal agents in inactivating coronaviruses](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1693.md)
* [Effectiveness of the anti-sars-cov-2 coatings](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2459.md)
* [Efficacy of disinfectants](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3387.md)
* [Efficient replication in upper respiratory tract](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2622.md)
* [Enveloped viruses like mhv coronavirus are susceptible to inactivation by mechanical stress.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_543.md)
* [Existing poor health conditions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3141.md)
* [Exposure to chemical and biological contaminants on push plates](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2567.md)
* [Exposure to sars-cov-2 in hospital environments](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2161.md)
* [Few risk calculators account for all three routes of transmission: fomite, airborne, and droplets, potentially underestimating the virus exposure dose for occupants.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1174.md)
* [Founding a nonprofit project providing wastewater-based health assessments](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1359.md)
* [Global spread of covid-19 cases from wuhan](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_257.md)
* [Health system vulnerability](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1482.md)
* [Herd immunity and vaccine effectiveness in ageing populations](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_656.md)
* [High exposure to global trade and gvc-integration leading to vulnerability to contagious diseases propagation.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1484.md)
* [High infection rate via contaminated surfaces](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2377.md)
* [High mortality rates of known coronaviruses mers-cov, sars-cov](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3122.md)
* [High number of positive air and surface samples indicating potential contamination](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2334.md)
* [High occupant density facilitates the accrual of human-associated microorganisms](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_428.md)
* [High residential building density may facilitate disease transmission](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1162.md)
* [High susceptibility of population to the virus](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2899.md)
* [High transmission capability of covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3420.md)
* [Higher covid-19 mortality rate](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3433.md)
* [Higher fatality rates among older and immunocompromised individuals pose a significant risk to these population groups.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3435.md)
* [Higher infection rates linked to lower housing conditions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3440.md)
* [Higher risk of reinfection in unvaccinated individuals](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3491.md)
* [Highly contagious nature and relatively long incubation period of sars-cov-2 can lead to silent carriers and high basic reproductive number for covid-19 virus.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3493.md)
* [Highly resistant variants of covid-19 continue to emerge](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3961.md)
* [Human mucus barrier weakens with low humidity levels.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3962.md)
* [Human-to-human transmission through droplets, aerosols, and direct contact](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3963.md)
* [Identification of drugs with potential anti-coronavirus effects](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4017.md)
* [Identification of effective drug compounds](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4026.md)
* [Improper handling of the cold spray system and copper powder can lead to exposure to toxic copper dust.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4027.md)
* [Inability to accommodate increasing covid-19 cases in hospitals](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4143.md)
* [Inability to assess seasonal patterns and mutated versions of sars-cov-2](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4153.md)
* [Inability to sustain intensive npi packages for suppression may lead to rapid transmission rebound](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4458.md)
* [Inactivation of human coronaviruses with far-uvc light](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4772.md)
* [Inactivation of sars-cov-2 virus on the coated surface](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4777.md)
* [Inactivation of virus](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4888.md)
* [Inadequate antibacterial and antiviral properties of stainless steel surfaces](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4896.md)
* [Inadequate approach to managing the risk of vector-borne diseases like malaria](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4897.md)
* [Inadequate consideration of disease transmission risks in virtual interactions may result in the continuation of contagious disease spread despite advancements in remote technologies.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4898.md)
* [Inadequate effect on reducing peak value of infections](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4993.md)
* [Inadequate evaluation of drug therapies for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4998.md)
* [Inadequate evaluation of traditional medicinal plants for covid-19 treatment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5006.md)
* [Inadequate reduction in infected curves with a small number of infected humans](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5023.md)
* [Inadequate research and regulation of air-purifying plants may lead to inconsistent efficacy and potential health risks from plant-related allergens or toxins.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5025.md)
* [Inadequate respiratory system function](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5037.md)
* [Inadequate sensitivity and specificity of biosensors for covid-19 detection](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5047.md)
* [Inadequate simulation of real-life infectious disease scenarios in virtual reality training](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5048.md)
* [Inadequate utilization of urine proteomics for disease biomarkers](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5090.md)
* [Inadequate ventilation leading to poor indoor air quality and increased risk of disease transmission](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5178.md)
* [Incomplete inactivation of sars-cov-2 on copper-coated surfaces](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5179.md)
* [Increase in vaccination coverage to approximately 12% by the end of the study period](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5433.md)
* [Increased exposure risk associated with high occupant density and consistent contact demonstrated in covid-19 outbreaks](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5463.md)
* [Increased risk of infection due to crowded spaces around holographic displays](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5466.md)
* [Individuals continuously assess their protection status based on the adult mosquito population size and the prevalence of infected humans.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5482.md)
* [Ineffective control of the disease with low isolation rates](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5483.md)
* [Ineffective cure or treatment for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5499.md)
* [Ineffective decrease in mortality growth rate after lockdown](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5504.md)
* [Ineffective outbreak role index ori measurement leading to inadequate support and flexibility in healthcare](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5506.md)
* [Ineffectiveness of upper-room uv in protecting health care workers from airborne infection](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5511.md)
* [Inhalation of aerosols containing pathogens](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5628.md)
* [Insensitive to variations in viral species](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5691.md)
* [Insufficient disinfection of indoor air and surfaces](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5708.md)
* [Insufficient focus on post-covid-19-infection effects on patients](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5735.md)
* [Insufficient healthcare preparation](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5773.md)
* [Insufficient knowledge of covid-19 inactivation mechanisms on copper coatings](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5869.md)
* [Insufficient separation of different zones within homes leading to cross-contamination among different areas](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5934.md)
* [Insufficient testing and approval of medical inventions for disease prevention may lead to ineffective or unsafe products being used in the market](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5940.md)
* [Insufficient testing data](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6027.md)
* [Insufficient ventilation leading to indoor air stagnation and high pathogen concentration.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6029.md)
* [Insufficient virucidal testing leading to ineffective virus inactivation](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6440.md)
* [Insufficient virus reduction](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6441.md)
* [Interaction between susceptible subgroup and infectives with age-specific transmission potential](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6476.md)
* [Investigation of the therapeutic benefits of indoor horticultural activities for individuals at risk, such as those with age-related diseases](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6482.md)
* [Irregular shape and data acquisition difficulty may lead to ineffective grid regions for disease control and prevention.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6486.md)
* [Lack of access to testing](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6536.md)
* [Lack of antibacterial and antiviral properties in stainless steel surfaces](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6538.md)
* [Lack of conclusive evidence for the effectiveness of shl oral liquid against covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6581.md)
* [Lack of coronavirus vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6582.md)
* [Lack of covid-19 vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6584.md)
* [Lack of definite solution for treatment of covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6586.md)
* [Lack of drug therapies for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6589.md)
* [Lack of drug therapy options](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6590.md)
* [Lack of drugs and vaccines](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6591.md)
* [Lack of effective antiviral drug and vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6592.md)
* [Lack of effective drugs](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6593.md)
* [Lack of effective medical treatment for contagious diseases](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6755.md)
* [Lack of effective pharmaceutical interventions for new strains of pandemics](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6756.md)
* [Lack of effective pharmaceutical response](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6771.md)
* [Lack of effective treatment and vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6800.md)
* [Lack of effective treatment for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6836.md)
* [Lack of effective treatment for newly emerging infectious diseases such as covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6899.md)
* [Lack of effective vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6916.md)
* [Lack of effective vaccine for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7068.md)
* [Lack of effective vaccines for vector-borne diseases](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7113.md)
* [Lack of effectiveness and precision in virtual reality applications may impact patient care and treatment outcomes.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7114.md)
* [Lack of immunity and effective vaccine for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7118.md)
* [Lack of knowledge about the half-life persistence of virus markers in wastewater and its impact on sampling methods and measurement accuracy.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7119.md)
* [Lack of long-lasting antimicrobial coatings](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7120.md)
* [Lack of long-term protection](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7125.md)
* [Lack of medication and vaccines for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7127.md)
* [Lack of novel treatment options](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7308.md)
* [Lack of personal protection impact on outbreak size](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7450.md)
* [Lack of personal protection measures](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7632.md)
* [Lack of precise knowledge about upcoming pandemics and their spreading behavior](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7703.md)
* [Lack of preexisting immunities](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7704.md)
* [Lack of protective equipment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7721.md)
* [Lack of proven treatment for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7822.md)
* [Lack of qualitative data and victim voices in accounts of violence](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7823.md)
* [Lack of scientific advances and knowledge about diseases](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7884.md)
* [Lack of specific medicine or vaccine to control covid-19.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7885.md)
* [Lack of specific treatment or vaccine for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8034.md)
* [Lack of specific treatments and vaccines for coronavirus infections](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8045.md)
* [Lack of strong healthcare system](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8113.md)
* [Lack of testing](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8146.md)
* [Lack of trained rapid-response team to deal with suspected cases](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8246.md)
* [Lack of transformative impact in managing vbds like malaria](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8266.md)
* [Lack of treatment or vaccine for sars-cov-2](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8335.md)
* [Lack of vaccine and medications against covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8379.md)
* [Lack of vaccine for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8437.md)
* [Lack of vaccine or cure](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8521.md)
* [Lack of vaccine or specific drug treatment for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8703.md)
* [Lack of vaccines and agent-specific drugs](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8709.md)
* [Lack of ventilation and open spaces in multi-family residential buildings](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8714.md)
* [Lagging development of vaccines and medicine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8715.md)
* [Large number of confirmed covid-19 cases in europe](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8719.md)
* [Large stocks of vaccine not available for 18 months or more](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8841.md)
* [Large uncertainties around transmission of the virus and policy effectiveness](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9226.md)
* [Limited availability of medication and vaccines for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9434.md)
* [Limited diagnostic and screening tests](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9447.md)
* [Limited diagnostic tests](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9629.md)
* [Limited effectiveness of uvc radiation due to virus concealment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9701.md)
* [Limited efficacy against specific viruses](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9883.md)
* [Limited evidence for the effectiveness of barrier devices like n95 masks over simple surgical masks.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9923.md)
* [Limited proportion of immune individuals in the population](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9965.md)
* [Limited research in critical areas related to disease control and outbreak management](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9966.md)
* [Limited research on disinfection and killing mechanisms of sars-cov-2 on various surfaces.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9967.md)
* [Limited research on drug efficacy, safety, and antibody response](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9970.md)
* [Limited use of germicidal irradiation in civil buildings](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9973.md)
* [Liver transplant recipients with metabolic comorbidities](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9977.md)
* [Long incubation period of covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9978.md)
* [Low humidity levels allow droplets to become droplet nuclei, remain in the air for prolonged periods of time, and travel for long distances.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9979.md)
* [Low velocity personalized ventilation system may not effectively mitigate the propagation of contagious diseases.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9980.md)
* [Medical and psychological maladies due to stress and isolation](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9982.md)
* [Mild effect on reducing the peak value of covid-19 infections](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10269.md)
* [Nbpi has been adopted in various types of buildings, but its effectiveness in controlling the transmission of contagious diseases like coronaviruses needs to be further studied.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10289.md)
* [Need for multiple doses of covid-19 vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10408.md)
* [Need for treatments and approaches to combat specific viral proteins](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10443.md)
* [Need to triage and treat large numbers of patients with respiratory illness](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10465.md)
* [No definitive treatment or preventive vaccine for the coronavirus](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10589.md)
* [No standard vaccine or cure for covid-19.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10590.md)
* [Overwhelmed medical facilities during outbreaks](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10661.md)
* [Paucity of good quality data on uv-c irradiation of sars-cov-1, sars-cov-2, and mers-cov in the air](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10677.md)
* [Perception of inadequate or inappropriate care at hospitals](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10712.md)
* [Physical recovery or therapy in virtual reality may not fully replicate real-world outcomes](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10824.md)
* [Plasma therapy against covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_11032.md)
* [Poor removal of sars-cov-2 fragments in wastewater treatment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_11087.md)
* [Positive influence of employees in nursing professions on infection numbers](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_11564.md)
* [Positive samples from isolation rooms indicate potential spread of the virus to other areas](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_11669.md)
* [Possible covid-19 spreading due to lack of social isolation](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_11717.md)
* [Possible transmission of contagious diseases through untreated wastewater](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_11859.md)
* [Potential difference between lab conditions and real-world scenarios for metal surface exposure. this could affect the effectiveness of copper in mitigating the spread of the virus.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_11984.md)
* [Potential failure of other coating technologies amine and ammonium-based polymers to inactivate the virus](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12198.md)
* [Potential failure of vaccine efficacy in later clinical trials](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12203.md)
* [Potential spread of covid-19 within the building due to occupant distribution](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12206.md)
* [Potential spread of viruses due to aerosolization and sampling](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12207.md)
* [Potential transmission of contagious diseases through close contact during data collection](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12208.md)
* [Predicted increase in cases without vaccine availability](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12264.md)
* [Presence of genetic material of sars-cov-2 in urban wastewater as an indicator of potential virus presence in the area.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12499.md)
* [Problems with universal access to vaccines and their effectiveness](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12540.md)
* [Prolonged presence of covid-19 rna in feces after respiratory tract tests negative.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12806.md)
* [Quality of service as a measure of resilience](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12821.md)
* [Quality-related concerns over drug efficacy, safety, and surveillance](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12822.md)
* [Quality-related concerns over drug efficacy, safety, and surveillance for malaria prevention](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12823.md)
* [Rapid and widespread virus spread despite quarantine and lockdown measures.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_13029.md)
* [Reduced nk cell numbers observed during the acute phase of sars-cov-2 infection.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_13156.md)
* [Reliance on houseplants as a sole solution for air purification in naturally ventilated homes](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_13322.md)
* [Reliance on non-pharmaceutical interventions at the early stage of a pandemic](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_13710.md)
* [Reliance on traditional medicine for virus protection](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_13755.md)
* [Reliance on wastewater surveillance to estimate covid-19 presence and prevalence.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_13761.md)
* [Relocating businesses, schools, and housing across cities with unique transportation networks may impact the growth rate and evolution of epidemics.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_13930.md)
* [Representation and analysis of vaccine candidates](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14207.md)
* [Research institutions working 24/7 on drug and vaccine development](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14214.md)
* [Research needs](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14220.md)
* [Rising cases of fungal and viral resistances posing significant threats](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14263.md)
* [Risk of ineffective anti-sars-cov-2 coatings](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14273.md)
* [Risk of infection through face-to-face contact](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14282.md)
* [Risk of new variants and mutations](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14293.md)
* [Risk of novel rna viruses presenting a serious threat to global public health and disease control](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14341.md)
* [Risk of resistance development to anti-sars-cov-2 coatings](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14342.md)
* [Risk of viral integration in human lung host cells](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14412.md)
* [Risk of virus transmission through shared touch surfaces on holographic display interfaces](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14464.md)
* [Risk of waning efficacy](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15007.md)
* [Risks associated with the use of copper as a virus-inactivating solution](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15009.md)
* [Rollout of mass drug-administration campaigns in response to unsubstantiated recommendations, causing diversion of drug supplies from neglected disease programs.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15425.md)
* [Safety concerns with alternative ventilator designs](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15426.md)
* [Sars-cov-2 persisting on surfaces for up to 4 days at room temperature](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15434.md)
* [Scarcity of research](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15435.md)
* [Selection of materials with antimicrobial properties](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15436.md)
* [Similar stability to sars-cov-1](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15675.md)
* [Strong and statistically significant correlation between prevalence of obesity and covid-19 mortality rate](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15789.md)
* [Swift and dramatic inactivation of sars-cov-2 by the cu 2 o/pu coating, reducing the viral titer by 99.9% in 1 hour.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15802.md)
* [Testing alone was not enough to reduce r0 below 1 but effectively reduced transmission when paired with high-quality infection control practices.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15929.md)
* [The effectiveness of test and trace depends strongly on coverage and the timeliness of contact tracing.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16034.md)
* [Tissue tropism](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16214.md)
* [Tissue tropism and pathogenesis of sars-cov-2](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16249.md)
* [Transmission of coronaviruses from contaminated surfaces to hands](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16345.md)
* [Transmission of covid-19 through aerosols](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16346.md)
* [Transmission of respiratory droplets containing contagious diseases](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16435.md)
* [Transmission of rna and dna viruses](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16605.md)
* [Transmission through direct or indirect contact with infected people or contaminated surfaces](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17046.md)
* [Treatment of covid-19 is mostly symptomatic](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17048.md)
* [Uncertain virucidal activity against specific viruses, such as sars-cov-2](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17062.md)
* [Uncertainty and irregular shape of traditional unit for quarantine measures](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17064.md)
* [Uncertainty in identifying the source of the virus](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17210.md)
* [Uncertainty in the reproduction number r0 and severity of the virus](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17218.md)
* [Uncertainty regarding the effectiveness of copper coatings on 3d-printed surfaces in inactivating the covid-19 virus.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17331.md)
* [Uncertainty regarding the excretion-route distribution of virus markers , fecal versus urine and unknown importance for different markers.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17336.md)
* [Unclear efficacy of protection against re-infections in people with and without symptoms at their initial sars-cov-2 infection](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17340.md)
* [Unconfirmed effects of nursing on infection incidence in older regions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17341.md)
* [Unknown chemical groups to inactivate sars-cov-2](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17523.md)
* [Unmitigated epidemic with predicted deaths](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17604.md)
* [Unpredictable bacterial and viral infections](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17628.md)
* [Unwillingness or inability to invest in specialized medical devices or wearables](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17629.md)
* [Use of copper-coated surfaces for mitigating sars-cov-2 propagation.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17631.md)
* [Use of drugs in treatment of sars-cov-2 infection](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18001.md)
* [Use of ehealth wearables for covid-19 data interpretation and monitoring.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18053.md)
* [Use of high fidelity mobile holographic capability may lead to increased physical interaction and close proximity among individuals, potentially facilitating the spread of contagious diseases.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18189.md)
* [Use of human wastewater to track diseases](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18200.md)
* [Use of respiratory rate monitoring for disease evaluation](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18210.md)
* [Use of unapproved drugs for covid-19 treatment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18564.md)
* [Utilization of wearable devices in the healthcare system.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18788.md)
* [Variability in pathogen infectivity due to virulence, pathogen generation, and infective dose](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19098.md)
* [Variability in the percentage of recovered patients required for herd immunity](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19214.md)
* [Variation in protection against re-infections](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19545.md)
* [Varied efficacy of copper surfaces based on copper content and form native, nanoparticle raises concerns about the uniformity of antiviral properties across different copper materials.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19568.md)
* [Virus accumulation](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19590.md)
* [Virus inactivation](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19950.md)
* [Virus mutation challenges vaccine development](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19952.md)
* [Viruses and bacteria thrive on dry conditions.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_20038.md)
* [Visits to agricultural lands by older individuals outside of urban areas increases risk of contagious disease spread.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_20414.md)
* [Visits to gardens by individuals residing in non-urbanized areas increases risk of contagious disease spread.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_20476.md)
* [Visits to parks by younger individuals in urban areas increases risk of contagious disease spread.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_20688.md)
* [Waning efficacy of vaccines](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_20736.md)
* [Whole-room uv-c system effectiveness against rna viruses like mhv-a59, mers-cov, and sars-cov.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_20894.md)
* [Wide array of endogenous chemical and biological urinary biomarkers linked with disease](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_20895.md)

## Property: has_RiskGroup_BPIntervention

* [Environmental parameters control](https://github.com/mm80843/T3.5/blob/pages/BP_Intervention/PBN__BP_Intervention_29.md)
* [Infection tracking / monitoring](https://github.com/mm80843/T3.5/blob/pages/BP_Intervention/PBN__BP_Intervention_38.md)
* [Quarantine support](https://github.com/mm80843/T3.5/blob/pages/BP_Intervention/PBN__BP_Intervention_30.md)
* [Raising awareness](https://github.com/mm80843/T3.5/blob/pages/BP_Intervention/PBN__BP_Intervention_33.md)
* [Support recovery of sectors via remote work](https://github.com/mm80843/T3.5/blob/pages/BP_Intervention/PBN__BP_Intervention_1.md)

## Property: has_RiskSubgroup_OwnerGroup

* [Building managers](https://github.com/mm80843/T3.5/blob/pages/StakeholderGroup/PBN__StakeholderGroup_7.md)
* [City authorities](https://github.com/mm80843/T3.5/blob/pages/StakeholderGroup/PBN__StakeholderGroup_1.md)
* [Facility maintenance team](https://github.com/mm80843/T3.5/blob/pages/StakeholderGroup/PBN__StakeholderGroup_0.md)
* [Government departments](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_5.md)
* [Government institutions](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_15.md)
* [Health organisations](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_25.md)
* [Medical and healthcare personnel](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_2.md)
* [Private health organisations](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_14.md)
* [Project managers](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_13.md)
* [Public health authorities](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_139.md)
* [Public health authorities and data management organizations](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_1.md)
* [Research institutions](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_34.md)
* [Research organisations](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_57.md)

## Property: has_RiskSubgroup_SubjectGroup

* [Government institutions](https://github.com/mm80843/T3.5/blob/pages/StakeholderGroup/PBN__StakeholderGroup_7.md)
* [Health organisations](https://github.com/mm80843/T3.5/blob/pages/StakeholderGroup/PBN__StakeholderGroup_1.md)
* [Research organisations](https://github.com/mm80843/T3.5/blob/pages/StakeholderGroup/PBN__StakeholderGroup_0.md)

## Property: has_RiskSubgroup_SubjectSubgroup

* [Building managers](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_5.md)
* [City authorities](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_15.md)
* [Facility maintenance team](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_25.md)
* [Government departments](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_2.md)
* [Medical and healthcare personnel](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_14.md)
* [Private health organisations](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_13.md)
* [Project managers](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_139.md)
* [Public health authorities](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_1.md)
* [Public health authorities and data management organizations](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_34.md)
* [Research institutions](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_57.md)

## Property: has_RiskSubgroup_TechGroup

* [Air control](https://github.com/mm80843/T3.5/blob/pages/TechGroup/PBN__TechGroup_2.md)
* [Data analytics](https://github.com/mm80843/T3.5/blob/pages/TechGroup/PBN__TechGroup_12.md)
* [Healthcare](https://github.com/mm80843/T3.5/blob/pages/TechGroup/PBN__TechGroup_6.md)

## Property: has_RiskSubgroup_TechSubgroup

* [Air filtering](https://github.com/mm80843/T3.5/blob/pages/TechSubgroup/PBN__TechSubgroup_7.md)
* [Analytical chemistry](https://github.com/mm80843/T3.5/blob/pages/TechSubgroup/PBN__TechSubgroup_6.md)
* [Diagnostic testing](https://github.com/mm80843/T3.5/blob/pages/TechSubgroup/PBN__TechSubgroup_66.md)
* [Personal hygiene and sanitation](https://github.com/mm80843/T3.5/blob/pages/TechSubgroup/PBN__TechSubgroup_29.md)
* [Physical health monitoring](https://github.com/mm80843/T3.5/blob/pages/TechSubgroup/PBN__TechSubgroup_42.md)
* [Remote healthcare and telemedicine](https://github.com/mm80843/T3.5/blob/pages/TechSubgroup/PBN__TechSubgroup_20.md)
* [Vaccination development and distribution](https://github.com/mm80843/T3.5/blob/pages/TechSubgroup/PBN__TechSubgroup_2.md)
* [Ventilation](https://github.com/mm80843/T3.5/blob/pages/TechSubgroup/PBN__TechSubgroup_39.md)
* [Ventilation and air quality systems](https://github.com/mm80843/T3.5/blob/pages/TechSubgroup/PBN__TechSubgroup_117.md)
* [Wellbeing and mental health](https://github.com/mm80843/T3.5/blob/pages/TechSubgroup/PBN__TechSubgroup_19.md)

